About Axio

// News - 2014

Axio Leading Panel Discussion at the 2015 Joint Statistical Meeting

FOR IMMEDIATE RELEASE

Contact:
Mr. Michael Antinore, PhD.
Axio Research, LLC
(206) 577-0225
michaela@axioresearch.com

Seattle, Wash, November 19, 2014 – Axio Research announced today that David Kerr, M.S., is invited to chair a panel discussion entitled “DMC Decision Making; Behind Closed Doors” at the 2015 Joint Statistical Meeting, to be held August 9–13, 2015, at the Washington State Convention Center in Seattle. Mr. Kerr will lead a panel of experienced Biostatisticians in a discussion intended to provide insight into how Data Monitoring Committees arrive at their recommendations.

Mr. Kerr, the Director of DMC Services at Axio Research, has over 20 years of experience providing statistical support to DMC's.

For more information about the Conference, please visit JSM 2015 Seattle.

About Axio Research (WWW.AXIORESEARCH.COM)

Founded by an internationally recognized group of biostatisticians in 1979, Axio Research has over 30 years of experience supporting pharmaceutical and biotechnology companies. Axio services range from providing data management, biostatisticial and DMC support to medical writing, statistical report writing, clinical event adjudication and custom web-based data collection tools. Axio staff experience includes working on projects ranging from small data management projects to DMC report generation for complex multi-center studies with hundreds of sites and thousands of patients.

The Axio Research is headquartered in Seattle, WA.

Axio Presenting at the ORCA Special All–Day Educational Meeting

FOR IMMEDIATE RELEASE

Contact:
Mr. Michael Antinore, PhD.
Axio Research, LLC
(206) 577-0225
michaela@axioresearch.com

Seattle, Wash, November 17, 2014 – Axio Research announced today that David Kerr, M.S., presented a talk entitled “DMC's; Reviewing Conduct Safety, and Efficacy to Protect Study Participants” and participated in a panel discussion entitled “Q&A's; Safety Reporting and Related Considerations” at the Organization of Regulatory and Clinical Associates (ORCA) Special Meeting – Clinical Updates, helpd November 17, 2014 in Seattle.

Mr. Kerr, the Director of DMC Services at Axio Research, has over 20 years of experience providing statistical support to DMC's.

For more information about the Conference, please visit ORCA November 2014 Meeting Information.

About Axio Research (WWW.AXIORESEARCH.COM)

Founded by an internationally recognized group of biostatisticians in 1979, Axio Research has over 30 years of experience supporting pharmaceutical and biotechnology companies. Axio services range from providing data management, biostatisticial and DMC support to medical writing, statistical report writing, clinical event adjudication and custom web-based data collection tools. Axio staff experience includes working on projects ranging from small data management projects to DMC report generation for complex multi-center studies with hundreds of sites and thousands of patients.

The Axio Research is headquartered in Seattle, WA.

Axio Launches Statistical Genetics & Genomics Services

–  New division focused on supporting translation of complex genomic data for drug discovery, drug repositioning, and companion diagnostics development  –

FOR IMMEDIATE RELEASE

Contact:
Mr. Michael Antinore, PhD.
Axio Research, LLC
(206) 577-0225
michaela@axioresearch.com

Seattle, Wash, September 23, 2014 – Axio Research announced today the launch of Statistical Genetics and Genomics services in response to the biopharmaceutical industry's need for advanced statistical support in the analysis and interpretation of complex genomic data for drug discovery and development, drug repositioning, and companion diagnostics development. “Pharmaceutical and biotechnology companies have a great need for advanced statistical analysis capabilities to address the challenge of interpreting the complex data sets being generated by genomic assays–specifically those in next–generation sequencing,” said Lee Hooks, Chief Executive Officer of Axio. “With the launch of this new services division, Axio now offers state–of–the–art statistical genetics and statistical genomics capabilities and methodologies to researchers seeking to uncover specific genetic components of complex human disorders and quantitative traits, as well as to advance new and enhanced drugs and diagnostics.”

The new interdisciplinary Statistical Genetics and Genomics division combines Axio's deep expertise in biostatistics, bioinformatics, and clinical understanding with additional new capabilities in statistical genetics and will be led by David Henderson, Ph.D., who has joined the company as Director of Statistical Genetics. Dr. Henderson and his team of PhD/MS staff will apply leading-edge statistical and computational methods focused on:

  • Analysis of large-scale data sets from genome-wide association studies (GWAS) as well as methylation, gene expression, genotyping, copy-number variation (CNV), and next-generation sequencing experiments
  • Assisting clients in experimental design
  • Developing tools for analysis and for graphical display of analysis results

“As next-generation sequencing and other technologies generate evermore complex genetic and genomic data sets, statistical methods must continue to evolve and emerge for studying the genetic components of clinical traits,” said Dr. Henderson. “I'm excited to join Axio in providing this premium resource at the leading edge of statistical genetics to investigators seeking to identify genes and genetic variations underlying diseases. In particular, I expect the application of Axio's deep clinical experience to these challenges will provide substantial benefit to our clients and prove to be a significant differentiator of our services.”

In the newly created position of Director of Statistical Genetics, Dr. Henderson brings to Axio more than 20 years of experience in genetics, genomics, statistics, and statistical computing. Prior to joining Axio, he provided business consulting services to pharmaceutical and biotechnology companies for experimental design, data analysis, and interpretation of results from genomic and genetic data at LabCorp Clinical Trials, Covance, Sage Bionetworks, and Rosetta Inpharmatics. Dr. Henderson holds a B.Sc. in Animal Science from Texas A&M University, an M.Sc. in Molecular Genetics from South Dakota State University, and a Ph.D. in Statistical Genetics from Virginia Polytechnic Institute and State University.

About Axio Research (WWW.AXIORESEARCH.COM)

Founded by an internationally recognized group of biostatisticians in 1979, Axio Research has over 30 years of experience supporting pharmaceutical and biotechnology companies. Axio services range from providing data management, biostatisticial and DMC support to medical writing, statistical report writing, clinical event adjudication and custom web-based data collection tools. Axio staff experience includes working on projects ranging from small data management projects to DMC report generation for complex multi-center studies with hundreds of sites and thousands of patients.

The Axio Research is headquartered in Seattle, WA.

Axio Presentations at 2014 SAS Software Conference

FOR IMMEDIATE RELEASE

Contact:
Mr. Michael Antinore, PhD.
Axio Research, LLC
(206) 577-0225
michaela@axioresearch.com

Seattle, Wash, July 22, 2014 – Axio Research announced today that Dr. William Coar, Ph.D., has been invited to present his paper “Automation of Appending Reports: A Sexy New Look” at the 2014 Western Users of SAS Software (WUSS) Educational Forum and Conference, September 3–5, 2014, at The Fairmont San Jose. In addition, Dr. Coar will be joined by Amber Randall, Axio's Manager of SAS Programming in presenting an e-Poster titled “Infrastructure for Growth.”

Axio Research continues to strive for excellence in SAS programming by being active and supporting local, regional and national SAS Users Groups. To that end, Axio is sponsoring the Hands–On Workshops for WUSS 2014.

For more information about the Conference, please visit WUSS 2014 Educational Forum and Conference.

About Axio Research (WWW.AXIORESEARCH.COM)

Founded by an internationally recognized group of biostatisticians in 1979, Axio Research has over 30 years of experience supporting pharmaceutical and biotechnology companies. Axio services range from providing data management, biostatisticial and DMC support to medical writing, statistical report writing, clinical event adjudication and custom web-based data collection tools. Axio staff experience includes working on projects ranging from small data management projects to DMC report generation for complex multi-center studies with hundreds of sites and thousands of patients.

The Axio Research is headquartered in Seattle, WA.

Ruth McBride Co–Authors New England Journal of Medicine Letter

FOR IMMEDIATE RELEASE

Contact:
Mr. Michael Antinore, PhD.
Axio Research, LLC
(206) 577-0225
michaela@axioresearch.com

Seattle, Wash, July 17, 2014 – Ruth McBride, Scientific Director at Axio Research, co–authored a Letter to the Editor published in the New England Journal of Medicine entitled “Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial”. In the letter, the investigators present the rates of serious adverse events in the AIM–HIGH trial. While exploratory, the analysis indicates that treatment with extended–release niacin was associated with significantly increased rates of certain serious adverse events, as well as increased rates of dose reductions or drug discontinuation related in most cases to known side effects of niacin.

Axio served as the Data Coordinating Center (DCC) for AIM–HIGH, a large multi–center clinical trial sponsored by the NHLBI with additional support from Abbott Laboratories. Ruth McBride, Scientific Director at Axio, served as the Co–Director for the AIM–HIGH DCC. The original trial results were published in the New England Journal of Medicine in December 2011

For more information about the AIM–HIGH Trial results, please visit Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy.

For more information about the Letter to the Editor, please visit Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial.

About Axio Research (WWW.AXIORESEARCH.COM)

Founded by an internationally recognized group of biostatisticians in 1979, Axio Research has over 30 years of experience supporting pharmaceutical and biotechnology companies. Axio services range from providing data management, biostatisticial and DMC support to medical writing, statistical report writing, clinical event adjudication and custom web-based data collection tools. Axio staff experience includes working on projects ranging from small data management projects to DMC report generation for complex multi-center studies with hundreds of sites and thousands of patients.

The Axio Research is headquartered in Seattle, WA.

© 2012-2014 Axio Research | Site Map | Contact Us